Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.

Over 100 years of scientific investigation has established that angiotensin-converting enzyme (ACE) plays an important role in both the renin-angiotensin system and the kinin-kallekrein system. ACE inhibitors--which stem the production of angiotensin II, a potent vasoconstrictor--have proved to be useful agents in the management of hypertension, in the prevention and treatment of heart failure, and in the improvement of endothelial function. Generally, ACE inhibitors are as efficacious as beta blockers and thiazide diuretics in reducing blood pressure and also induce regression of left ventricular hypertrophy. Many trials-including the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), the Veteran's Administration Cooperative Vasodilator-Heart Failure Trial (V-HeFT I), the Studies of Left Ventricular Dysfunction (SOLVD), and the Survival and Ventricular Enlargement (SAVE) trial--have demonstrated the ability of ACE inhibitors to reduce mortality within a wide range of heart failure, from asymptomatic left ventricular dysfunction to severe heart failure. The SAVE trial specifically evaluated the effects on post-myocardial infarction mortality and remodeling and found that ACE inhibitors were effective in reducing both. Further studies are assessing the potential additional antiatherosclerotic aspects of ACE inhibitors. Initial research indicates a reversal of endothelial dysfunction in atherosclerotic animals, and subsequent clinical trials, including the Trial on Reversing ENdothelial Dysfunction (TREND), support the likelihood of a similar effect in humans. Beneficial effects in hypertension or heart failure may also be gained with other interruptors of the renin-angiotensin system, such as angiotensin receptor blockers. Results from studies assessing these receptor blockers will bring greater understanding to the mechanism of action of ACE inhibitors.
AuthorsW W Parmley
JournalThe American journal of medicine (Am J Med) Vol. 105 Issue 1A Pg. 27S-31S (Jul 6 1998) ISSN: 0002-9343 [Print] UNITED STATES
PMID9707265 (Publication Type: Journal Article, Review)
Chemical References
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
  • Clinical Trials as Topic
  • Endothelium, Vascular (drug effects, physiopathology)
  • Heart Failure (drug therapy, physiopathology)
  • Humans
  • Hypertension (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: